GlaxoSmithKline (GSK) Announces Earnings Results

GlaxoSmithKline (LON:GSK) issued its quarterly earnings results on Wednesday. The company reported GBX 111.80 ($1.57) earnings per share for the quarter, beating the Zacks’ consensus estimate of GBX 110.90 ($1.55) by GBX 0.90 ($0.01), Digital Look Earnings reports. GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%. The company had revenue of £76,390 billion during the quarter.

Shares of GlaxoSmithKline (GSK) traded down GBX 12.80 ($0.18) during mid-day trading on Friday, reaching GBX 1,291 ($18.10). The company had a trading volume of 11,683,099 shares, compared to its average volume of 9,220,000. The firm has a market capitalization of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.32) and a 1 year high of GBX 1,724.50 ($24.18).

A number of research firms recently commented on GSK. Goldman Sachs Group restated a “buy” rating and issued a GBX 1,900 ($26.64) price objective on shares of GlaxoSmithKline in a report on Tuesday, October 17th. S&P Global set a GBX 1,500 ($21.03) price target on GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday, October 26th. HSBC reiterated a “buy” rating and set a GBX 1,925 ($26.99) price target on shares of GlaxoSmithKline in a report on Wednesday, November 22nd. Morgan Stanley set a GBX 1,450 ($20.33) price target on GlaxoSmithKline and gave the company a “sell” rating in a report on Monday, November 6th. Finally, Kepler Capital Markets lowered their price target on GlaxoSmithKline from GBX 1,520 ($21.31) to GBX 1,340 ($18.79) and set a “reduce” rating on the stock in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of GBX 1,541.36 ($21.61).

In other news, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Also, insider Sir Roy Anderson bought 562 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were bought at an average price of GBX 1,278 ($17.92) per share, with a total value of £7,182.36 ($10,070.61). Over the last quarter, insiders purchased 581 shares of company stock valued at $743,284.

TRADEMARK VIOLATION WARNING: “GlaxoSmithKline (GSK) Announces Earnings Results” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.com-unik.info/2018/02/09/glaxosmithkline-gsk-announces-earnings-results.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit